TMP-301 / Tempero Bio 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  TMP-301 / Tempero Bio
    Enrollment closed:  Multiple Ascending Dose Study of TMP-301 in Healthy Subjects (clinicaltrials.gov) -  Dec 11, 2023   
    P1,  N=32, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  TMP-301 / Tempero Bio
    Trial completion:  Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 (clinicaltrials.gov) -  Apr 29, 2021   
    P1,  N=71, Completed, 
    Our data indicate for the first time that a consistent, unified relationship can be observed between exposure and mGlu receptor occupancy when unbound brain concentration and receptor affinity are taken into account across a range of species for a diverse set of mGlu NAMs, including a new drug candidate, HTL0014242. Recruiting --> Completed
  • ||||||||||  TMP-301 / Tempero Bio
    Trial completion date, Trial primary completion date:  Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 (clinicaltrials.gov) -  Oct 26, 2020   
    P1,  N=78, Recruiting, 
    Trial completion date: Mar 2021 --> Aug 2021 | Trial primary completion date: Mar 2021 --> Aug 2021 Trial completion date: May 2020 --> May 2021 | Trial primary completion date: Apr 2020 --> Jan 2021
  • ||||||||||  TMP-301 / Tempero Bio
    Trial completion date, Trial primary completion date:  Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects (clinicaltrials.gov) -  Oct 26, 2020   
    P1,  N=10, Recruiting, 
    Trial completion date: May 2020 --> May 2021 | Trial primary completion date: Apr 2020 --> Jan 2021 Trial completion date: Nov 2020 --> Mar 2021 | Trial primary completion date: Nov 2020 --> Mar 2021
  • ||||||||||  HTL0014242 / Sosei
    Journal:  Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators. (Pubmed Central) -  Oct 1, 2020   
    An alternative approach to drug discovery is to use structural knowledge to enable structure-based drug design (SBDD), which allows the design of molecules in a more rational, rather than empirical, fashion. Here we will describe the process of SBDD in the discovery of the mGlu negative allosteric modulator HTL0014242 and describe how knowledge of receptor structure can also be used to gain insights into the receptor activation mechanisms.
  • ||||||||||  TMP-301 / Tempero Bio
    Enrollment change, Trial completion date, Trial primary completion date:  Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242 (clinicaltrials.gov) -  Nov 9, 2019   
    P1,  N=78, Recruiting, 
    Here we will describe the process of SBDD in the discovery of the mGlu negative allosteric modulator HTL0014242 and describe how knowledge of receptor structure can also be used to gain insights into the receptor activation mechanisms. N=48 --> 78 | Trial completion date: Aug 2019 --> May 2020 | Trial primary completion date: Jul 2019 --> Apr 2020